FDA Pulls Plug on Two Drugs at Companies' Own Request
Published Date: 5/30/2025
Notice
Summary
The FDA is officially pulling the plug on two drug approvals from Meda AB and B. Braun Medical, Inc. because the companies told the FDA they stopped selling these drugs. This means these drugs won’t be available anymore, but no one will lose money or face surprises since the companies asked for this. If you used these drugs, it’s time to check with your doctor for alternatives!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Two Drugs Removed From Market
The FDA is withdrawing approval of two new drug applications from Meda AB and B. Braun Medical, Inc. because those companies told the FDA they stopped marketing the products and asked for withdrawal. The drugs will no longer be available, and the FDA says no one will lose money or face surprises because the companies requested this; if you used these drugs, check with your doctor about alternatives.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
Previous / Next Documents
Previous: 2025-09780 — Agency Information Collection Proposed Extension
The Energy Information Administration (EIA) wants to keep collecting important info on natural gas liquids and oil and gas reserves for three more years, with some updates to the forms. They’re also keeping one survey paused for now. If you’re involved in the energy industry, this affects you, and the EIA is asking for your thoughts before moving forward—so don’t miss the chance to weigh in!
Next: 2025-09782 — Polypropylene Corrugated Boxes From the People's Republic of China: Postponement of Preliminary Determination in the Countervailing Duty Investigation
The U.S. is investigating if Chinese polypropylene corrugated boxes get unfair government help. The first big decision on this is delayed from June 11 to a later date to give everyone more time to cooperate and sort out tricky details. This affects importers, manufacturers, and anyone watching trade rules, with possible impacts on duties and prices down the line.